Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 24-38, 2008; 10.1373/clinchem.2007.097360
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Packard, R. R. S.
Right arrow Articles by Libby, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Packard, R. R. S.
Right arrow Articles by Libby, P.
(Clinical Chemistry. 2008;54:24-38.)
© 2008 American Association for Clinical Chemistry, Inc.

Review

Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction

René R. S. Packard and Peter Libbya

Leducq Center for Cardiovascular Research, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

aAddress correspondence to this author at: Leducq Center for Cardiovascular Research, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB 7, Boston, MA 02115. e-mail plibby{at}rics.bwh.harvard.edu.

Recent investigations of atherosclerosis have focused on inflammation, providing new insight into mechanisms of disease. Inflammatory cytokines involved in vascular inflammation stimulate the generation of endothelial adhesion molecules, proteases, and other mediators, which may enter the circulation in soluble form. These primary cytokines also induce production of the messenger cytokine interleukin-6, which stimulates the liver to increase production of acute-phase reactants such as C-reactive protein. In addition, platelets and adipose tissue can generate inflammatory mediators relevant to atherothrombosis. Despite the irreplaceable utility of plasma lipid profiles in assessment of atherosclerotic risk, these profiles provide an incomplete picture. Indeed, many cardiovascular events occur in individuals with plasma cholesterol concentrations below the National Cholesterol Education Program thresholds of 200 mg/dL for total cholesterol and 130 mg/dL for low-density lipoprotein (LDL) cholesterol. The concept of the involvement of inflammation in atherosclerosis has spurred the discovery and adoption of inflammatory biomarkers for cardiovascular risk prediction. C-reactive protein is currently the best validated inflammatory biomarker; in addition, soluble CD40 ligand, adiponectin, interleukin 18, and matrix metalloproteinase 9 may provide additional information for cardiovascular risk stratification and prediction. This review retraces the biology of atherothrombosis and the evidence supporting the role of inflammatory biomarkers in predicting primary cardiovascular events in this biologic context.




The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Pathol.Home page
B. D. Lamon and D. P. Hajjar
Inflammation at the Molecular Interface of Atherogenesis: An Anthropological Journey
Am. J. Pathol., November 1, 2008; 173(5): 1253 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Aukrust, B. Halvorsen, A. Yndestad, T. Ueland, E. Oie, K. Otterdal, L. Gullestad, and J. K. Damas
Chemokines and Cardiovascular Risk
Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M.-T. Lin, S.-J. Chen, Y.-L. Ho, K.-C. Huang, C.-A. Chen, S.-N. Chiu, L.-C. Sun, W.-J. Lee, H.-C. Chen, J.-K. Wang, et al.
Abnormal Matrix Remodeling in Adolescents and Young Adults with Kawasaki Disease Late after Onset
Clin. Chem., November 1, 2008; 54(11): 1815 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Hao, M. Tan, X. Xu, and M.-Z. Cui
Histamine Induces Egr-1 Expression in Human Aortic Endothelial Cells via the H1 Receptor-mediated Protein Kinase C{delta}-dependent ERK Activation Pathway
J. Biol. Chem., October 3, 2008; 283(40): 26928 - 26936.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
I. Steinfeld, R. Navon, D. Ardigo, I. Zavaroni, and Z. Yakhini
Clinically driven semi-supervised class discovery in gene expression data
Bioinformatics, August 15, 2008; 24(16): i90 - i97.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. A. Duprez
Genetic Variants of Inflammatory Markers and Arterial Stiffness
Hypertension, June 1, 2008; 51(6): 1472 - 1473.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
B. Ponnuchamy and R. A. Khalil
Role of ADAMs in Endothelial Cell Permeability: Cadherin Shedding and Leukocyte Rolling
Circ. Res., May 23, 2008; 102(10): 1139 - 1142.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
U. M. Breland, B. Halvorsen, J. Hol, E. Oie, G. Paulsson-Berne, A. Yndestad, C. Smith, K. Otterdal, U. Hedin, T. Waehre, et al.
A Potential Role of the CXC Chemokine GRO{alpha} in Atherosclerosis and Plaque Destabilization: Downregulatory Effects of Statins
Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 1005 - 1011.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.